Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men by Wirtz, P H et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Oral melatonin reduces blood coagulation activity: a
placebo-controlled study in healthy young men
Wirtz, P H; Spillmann, M; Bärtschi, C; Ehlert, U; von Känel, R
Wirtz, P H; Spillmann, M; Bärtschi, C; Ehlert, U; von Känel, R (2008). Oral melatonin reduces blood coagulation
activity: a placebo-controlled study in healthy young men. Journal of Pineal Research, 44(2):127-133.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Pineal Research 2008, 44(2):127-133.
Wirtz, P H; Spillmann, M; Bärtschi, C; Ehlert, U; von Känel, R (2008). Oral melatonin reduces blood coagulation
activity: a placebo-controlled study in healthy young men. Journal of Pineal Research, 44(2):127-133.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Pineal Research 2008, 44(2):127-133.
Oral melatonin reduces blood coagulation activity: a
placebo-controlled study in healthy young men
Abstract
Melatonin has previously been suggested to affect hemostatic function but studies on the issue are scant.
We hypothesized that, in humans, oral administration of melatonin is associated with decreased plasma
levels of procoagulant hemostatic measures compared with placebo medication and that plasma
melatonin concentration shows an inverse association with procoagulant measures. Forty-six healthy
men (mean age 25 +/- 4 yr) were randomized, single-blinded, to either 3 mg of oral melatonin (n = 25)
or placebo medication (n = 21). One hour thereafter, levels of melatonin, fibrinogen, and D-dimer as
well as activities of coagulation factor VII (FVII:C) and VIII (FVIII:C) were measured in plasma.
Multivariate analysis of covariance and regression analysis controlled for age, body mass index, mean
arterial blood pressure, heart rate, and norepinephrine plasma level. Subjects on melatonin had
significantly lower mean levels of FVIII:C (81%, 95% CI 71-92 versus 103%, 95% CI 90-119; P =
0.018) and of fibrinogen (1.92 g/L, 95% CI 1.76-2.08 versus 2.26 g/L, 95% CI 2.09-2.43; P = 0.007)
than those on placebo explaining 14 and 17% of the respective variance. In all subjects, increased
plasma melatonin concentration independently predicted lower levels of FVIII:C (P = 0.037) and
fibrinogen (P = 0.022) explaining 9 and 11% of the respective variance. Melatonin medication and
plasma concentration were not significantly associated with FVII:C and D-dimer levels. A single dose
of oral melatonin was associated with lower plasma levels of procoagulant factors 60 min later. There
might be a dose-response relationship between the plasma concentration of melatonin and coagulation
activity.
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ABSTRACT 
Melatonin has previously been suggested to affect hemostatic function but studies on 
the issue are scant. We hypothesized that, in humans, oral administration of melatonin is 
associated with decreased plasma levels of procoagulant hemostatic measures compared to 
placebo medication and that plasma melatonin concentration shows an inverse association 
with procoagulant measures. Forty-six healthy men (mean age 25±4 years) were randomized, 
single-blinded, to either 3 mg of oral melatonin (n=25) or placebo medication (n=21). One 
hour thereafter, levels of melatonin, fibrinogen, and D-dimer as well as activities of 
coagulation factor VII (FVII:C) and VIII (FVIII:C) were measured in plasma. Multivariate 
analysis of covariance and regression analysis controlled for age, body mass index, mean 
arterial blood pressure, heart rate, and norepinephrine plasma level. Subjects on melatonin 
had significantly lower mean levels of FVIII:C (81%, 95% CI 71-92 vs. 103%, 95% CI 90-
119; p=0.018) and of fibrinogen (1.92 g/l, 95% CI 1.76-2.08 vs. 2.26 g/l, 95% CI 2.09-2.43; 
p=0.007) than those on placebo explaining 14% and 17% of the respective variance. In all 
subjects, increased plasma melatonin concentration independently predicted lower levels of 
FVIII:C (p=0.037) and fibrinogen (p=0.022) explaining 9% and 11% of the respective 
variance. Melatonin medication and plasma concentration were not significantly associated 
with FVII:C and D-dimer levels. A single dose of oral melatonin was associated with lower 
plasma levels of procoagulant factors 60 minutes later. There might be a dose-response 
relationship between the plasma concentration of melatonin and coagulation activity.  
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INTRODUCTION 
Melatonin has pleiotropic action [1] and alterations in its 24-hour profile could relate 
to a variety of pathological states amongst them cardiovascular disease. Oxidative stress, 
chronic systemic inflammation and coagulation activation are cornerstone mechanisms in the 
initiation and progression of atherothrombotic disease such as coronary artery disease (CAD) 
complicated by acute coronary syndromes [2-4]. By virtue of exerting antioxidative, 
antiinflammatory, and antithrombotic activity, endogenous melatonin could favorably 
influence the course of CAD [5-7].  
In support of this notion, nocturnal secretion of melatonin was found to be reduced in 
patients with CAD relative to healthy controls [8-10]. Patients with unstable angina showed 
lower melatonin excretion than those with stable angina suggesting that melatonin production 
was inversely associated with the risk of acute myocardial infarction (AMI) and cardiac death 
[11]. As compared to healthy controls, patients with AMI had lower elevation in serum 
melatonin at night than at day [12]. Melatonin has also been associated with biological risk 
factors for cardiovascular disease. For instance, circadian changes in melatonin may partially 
be responsible for light dark variations in the production of the inflammatory marker C-
reactive protein in patients with AMI [13]. In addition, patients with systemic hypertension 
who did not dip their blood pressure (BP) during the night showed lower nocturnal melatonin 
secretion than hypertensives who were night-time dippers [14].  
Oral melatonin given in a typical pharmacological dose of several milligrams does not 
mimic the endogenous profile but leads to supraphysiological levels with potentially 
therapeutic properties in terms of mechanisms involved in atherothrombotic diseases [6]. 
Intake of melatonin for three nights before sleep decreased 24-hour ambulatory BP in patients 
with systemic hypertension [15]. Melatonin in a dosage similar to the concentration of the 
nocturnal surge reduced leukocyte rolling and adhesion in the microcirculation of rats during 
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acute inflammation [16]. Aggregation of human platelets in vitro was inhibited by melatonin 
[17, 18] suggesting a relatively stronger inhibition with higher plasma melatonin 
concentration [17]. Melatonin also normalized shortened prothrombin time and elevated 
levels of fibrin degradation products in the blood of rats with thermal injury [19]. However, 
to the best of our knowledge, whether exogenously administered melatonin may influence 
steady-state coagulation activity in humans has not been explored. 
We investigated the effect of a single oral dose of 3 mg melatonin on plasma levels of 
coagulation factor VII activity (FVII:C), FVIII:C, fibrinogen, and D-dimer, all of which have 
previously been associated with an increased risk of coronary thrombotic events [20-23]. In 
brief, FVII together with tissue factor initiates the extrinsic pathway of blood coagulation 
when endothelial cells are damaged and prothrombotic material becomes exposed to the 
circulation [24]. Factor VIII is activated by thrombin further downstream in the coagulation 
cascade [25], where fibrinogen is ultimately converted to fibrin, the main component of a 
thrombus [26]. Dissolution of fibrin by the fibrinolytic system results in production of the 
fibrin degradation product D-dimer that is a coagulation activation marker reflecting the 
amount of fibrin formed during coagulation and subsequent fibrinolysis [27].  
We hypothesized that healthy young men allocated to melatonin would show lower 
plasma levels of FVIIC, FVIII:C, fibrinogen, and D-dimer relative to subjects allocated to 
placebo medication 60 min after administration of 3 mg of melatonin or placebo. We further 
hypothesized that plasma melatonin concentration would show an inverse relationship with 
levels of coagulation factors. We postulated that relationships between melatonin and 
coagulation activity would be independent of common demographic (i.e., age), metabolic 
(i.e., body mass index (BMI), mean arterial blood pressure (MAP), heart rate (HR)), and 
neuroendocrine (i.e., plasma norepinephrine) correlates of hemostatic function.  
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MATERIALS AND METHODS 
Participants and study design 
Our study sample consisted of 46 medication-free healthy men between 20 and 34 
years of age from whom we obtained complete data (Table 1). Subjects with any acute or 
chronic somatic or psychiatric disorders were excluded. Additional exclusion criteria, as 
obtained by subjects’ self-report, included regular strenuous exercise, smoking, alcohol and 
illicit drug abuse, heart disease, elevated blood sugar and diabetes, elevated cholesterol, liver 
and renal diseases, chronic obstructive pulmonary disease, allergies and atopic diathesis, 
rheumatic diseases, and current infectious diseases. If the personal history was not 
conclusive, the subjects’ primary care physician was contacted for clarification.  
We applied a randomized, placebo-controlled, single-blinded design (i.e. participants 
were unaware of whether they received verum or placebo medication). All subjects reported 
to the laboratory on two consecutive days. Participants abstained from food and drink (other 
than water) for 2 hours before reporting to the laboratory, and also from physical exercise, 
alcohol, and caffeinated beverages starting the evening before day 1. On day 1, systolic and 
diastolic blood pressure (BP), as well as HR, were measured once after subjects had been 
sitting quietly for 20 min, and BMI was also assessed. On day 2, sessions commenced 
between 14:00 h and 16:00 h and lasted for approximately 90 min. Twenty-five minutes after 
insertion of a venous catheter, melatonin or placebo was administered. Following previous 
observations on melatonin kinetics after oral intake of 1-5 mg of melatonin [28], we took 
blood samples under resting conditions 60 min after medication intake for assessment of 
coagulation activity, norepinephrine, and melatonin levels. The study protocol was formally 
approved by Switzerland’s regulatory agency for therapeutic products (Swissmedic) and the 
ethics committee of the State of Zurich, Switzerland. The study was carried out in accordance 
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with the Declaration of Helsinki principles. All participants provided written informed 
consent.  
 
Study medication 
Verum medication was 3 mg of melatonin purchased from Physiologics (“Melatonin 
Standard”, PhysioLogics, Northglenn, Col, 80234 USA, order No. 7915). Placebo pills 
contained lactose and amylum (lactosi cum amylo) and were purchased from Hänseler AG 
(Herisau, Switzerland, order No. 13-3400-2).  
 
Metabolic factors 
Systolic BP, diastolic BP and HR were measured using the fully automated Omron 
device (Omron 773, Omron Medizintechnik Handelsgesellschaft mbH, Mannheim, 
Germany). The MAP was computed by the formula (2/3* systolic BP plus 1/3* systolic BP) 
and used for statistical analysis. The BMI was calculated by dividing the weight in kilograms 
by the square of height in meters (kg/m2). 
 
Biochemical analyses 
For the determination of FVII:C, FVIII:C, fibrinogen and D-dimer, 4.5 ml of blood 
was added to 0.5 ml of citrate, 0.106 Mol/L. All samples were immediately centrifuged for 20 
min at 3000 x g at room temperature. Plasma aliquots were frozen in polypropylene test tubes 
at -80°C until further analyses. Fibrinogen levels were quantified in g/l as per a modified 
Clauss method [29]. FVII:C and FVIII:C were determined by standard coagulometric 
methods using factor-deficient standard human plasma and reagents (Dade Behring, 
Liederbach, Germany) and are expressed as % relative to normal plasma. D-dimer was 
determined in ng/ml using a commercially available enzyme-linked immunosorbent assay 
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(Asserachrom Stago, Asnières, France). All hemostatic measures were determined in 
duplicates, and all inter-and intra-assay coefficients of variation were <10%. 
For plasma norepinephrine and melatonin measurements, blood was drawn into 
EDTA-coated monovettes (ethylenediaminetetraacetic acid; Sarstedt, Numbrecht, Germany), 
and immediately centrifuged for 10 min at 2,000xg; plasma was stored at –80°C until 
analysis. Plasma norepinephrine and melatonin levels were determined by a commercial lab 
(Labor für Stressmonitoring, Göttingen, Germany). Norepinephrine levels were determined 
by means of high-performance liquid chromatography and electrochemical detection after 
liquid–liquid extraction [30]. Melatonin was extracted with methylene chloride and analysed 
with a reversed phase HPLC with fluorescence detection [31]. Detection limits were 10 pg/ml 
for norepinephrine and 2.5 pg/ml for melatonin. Samples with a melatonin concentration 
below the detection limit were set at half the limit of detection (i.e. 1.25 pg/ml) as was 
previously recommended for a skewed data set [32, 33]. Inter- and intra-assay coefficients of 
variation were <10% for all analyses. 
  
Statistical analysis 
All data were analysed using SPSS version 13.0 for Windows. Significance level was 
set at p<0.05 and all tests were two-tailed. Normal distribution of data was tested by the 
Kolmogorov-Smirnov test. As values of FVIII:C, D-dimer, and plasma melatonin were 
skewed we logarithmically transformed these data. Data are given as means ± SEM or as 
geometric means with 95% confidence interval. Differences in subjects’ characteristics 
between the melatonin and placebo group were calculated by the Student’s t-test. Pearson 
correlation analysis was used to estimate the bivariate correlation coefficient between two 
variables. 
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We applied multivariate analysis of variance (MANOVA; with medication as the 
between-groups factor), and multivariate analysis of covariance (MANCOVA; with age, 
BMI, MAP, HR, and norepinephrine levels as covariates) to test for a difference in 
coagulation measures between subjects with melatonin and those with placebo. The number 
and type of covariates were selected a priori given our sample size and based on the previous 
literature on variables possibly affecting coagulation function [34]. We employed multiple 
linear regression analysis to investigate the independent relationship between plasma 
melatonin levels and coagulation measures after forced entry of age, BMI, MAP, HR, and 
norepinephrine levels. Effect sizes are expressed as partial eta squared (ηp2) in MANOVA 
and MANCOVA and as R2 change in regression analysis. 
 
RESULTS 
Melatonin levels were expectedly higher in subjects who received melatonin than in 
those under placebo medication (Table 1). Of note, plasma melatonin levels varied largely 
within the melatonin group (17.3-2036.4 pg/ml) as opposed to the placebo group (1.3-8.6 
pg/ml). Heart rate was marginally higher in the group who received melatonin compared to 
the group with placebo medication. In contrast, age, BMI, MAP, and plasma norepinephrine 
levels were not significantly different between groups.  
In all subjects, FVIII:C levels correlated with mean arterial pressure (r=0.30, p=0.047) 
and norepinephrine levels (r=-0.31, p=.037). Fibrinogen levels correlated with levels of 
FVIII:C (r=0.34, p=0.022), and D-dimer (r=0.50, p<0.001). There was also a bivariate 
correlation reaching borderline significance between FVIII:C and D-dimer levels (r=0.25, 
p=0.093) and between fibrinogen and FVII:C (r=0.26, p=0.081). 
Multivariate ANOVA with medication (melatonin vs. placebo) as the between-group 
factor and the four coagulation measures as the dependent variables showed a trend towards 
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statistical significance for a medication effect (F4,41=2.27, p=0.078; ηp2 = 0.181). Table 2 
shows that FVIII:C levels were significantly lower in subjects with melatonin than in those 
with placebo (ηp2 = 0.087). There was also a trend towards statistical significance for lower 
fibrinogen levels in subjects with melatonin relative to those with placebo (ηp2 = 0.072). 
Multivariate ANCOVA controlling for age, BMI, MAP, HR, and norepinephrine 
levels showed a significant main effect for medication (F4,36=4.13, p=0.007; ηp2 = 0.314). As 
shown in Table 2, subjects who received melatonin had significantly lower levels of FVIII:C 
(ηp2 = 0.136) and fibrinogen (ηp2 = 0.172) than those who received placebo medication. 
In multivariate regression analysis, we computed the independent relationship 
between plasma levels of melatonin and coagulation measures adjusting for age, BMI, MAP; 
HR, and norepinephrine levels across all subjects. Table 3 shows that a lower melatonin 
concentration was significantly associated with higher levels of FVIII:C and fibrinogen 
explaining 9% and 11% of the respective variance. Figure 1 illustrates the independent 
relationship between the plasma melatonin concentration and levels of FVIII:C (Fig. 1A) and 
fibrinogen (Fig. 1B). Melatonin levels were not independently associated with D-dimer 
(p=0.96) and FVII:C (p=0.49) levels. 
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DISCUSSION 
To address the hypothesis that in humans, that administration of supraphysiological 
doses of melatonin would be associated with decreased plasma levels of procoagulant 
measures, we investigated the effect of a single oral dose of 3 mg melatonin on plasma levels 
of FVII:C, FVIII:C, fibrinogen, and D-dimer in young and healthy men. We found that, 60 
min after substance admininistration, subjects on melatonin had significantly lower mean 
levels of FVIII:C and of fibrinogen than those on placebo explaining 14% and 17% of the 
respective variance. These group differences are further supported by regression analyses in 
which increased plasma concentration of melatonin independently predicted lower levels of 
FVIII:C and fibrinogen explaining 9% and 11% of the respective variance. In other words, 
the higher the plasma melatonin concentration, the lower the plasma levels of FVIII:C and 
fibrinogen. Given that our placebo control group had higher levels of FVIII:C and fibrinogen 
compared to the melatonin group at a time when orally administered melatonin is known to 
reach maximum plasma levels [28], we may assume that melatonin was involved in 
mediating the decrease in these coagulation factors in the melatonin group. Particularly, there 
might be a dose-response relationship between the plasma concentration of melatonin and 
coagulation activity of FVIII and fibrinogen levels. Interestingly, melatonin intake did not 
affect levels of D-dimer and FVII:C suggesting melatonin administration might exert a 
selective effect on the plasma level of coagulation measures. 
What are the clinical implications of our findings and how do they fit with the 
literature?  Fibrinogen, which is converted to fibrin, the main component of a thrombus [26] 
has repeatedly emerged as a primary risk factor of cardiovascular disease [22, 35, 36]. Also 
FVIII:C, which becomes activated further downstream in the coagulation cascade by 
thrombin [25, 37] is associated with increased incidence of ischemic heart disease [21]. Our 
findings of lower levels of these cardiovascular risk factors after melatonin intake suggest a 
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cardioprotective and antithrombotic effect of melatonin. Such reasoning is in support of 
studies suggesting cardioprotection from exogenous melatonin administration by favorably 
affecting inflammatory and prothrombotic mechanisms pertinent to the manifestation of acute 
coronary syndromes. In animal models, melatonin reduced leukocyte rolling and adhesion in 
the microcirculation during acute inflammation [16] and normalized shortened prothrombin 
time and elevated levels of fibrin degradation products inflicted by thermal injury [19]. 
Melatonin infusion also reduced arrhythmias induced by experimental ischemia of the 
isolated rat heart [38]. In humans, platelet aggregation in vitro was inhibited by melatonin 
suggesting a dose-response effect [17, 18]. Moreover, findings on lowered nocturnal 
melatonin excretion in CAD patients relative to healthy controls further support a 
cardioprotective effect of melatonin [8-12]. To the best of our knowlegde our study is the first 
human in vivo study to show that administration of a single oral dose of melatonin is 
associated with decreased plasma levels of the procoagulant measures fibrinogen and 
FVIII:C. 
Which mechanisms could be involved in mediating this association? Previous 
findings suggest a role for catecholamines. We could previously show that acute systemic 
increase in catecholamines evokes a hypercoagulable state state [39]. Particularly, 
catecholamine infusion to healthy individuals increases plasma levels of FVIII:C [39]. Also, 
the magnitude of norepinephrine surge during acute mental stress was directly associated 
with increases in thrombin/antithrombin III complex (i.e. a marker of thrombin formation) 
[40] and D-dimer [41]. To account for a potential lowering effect of melatonin on 
catecholamine secretion as observed in other animal and human studies [42-46] we measured 
in our study norepinephrine. However, in contrast to other placebo-controlled studies on 
healthy young men [44, 46], we did not observe lower plasma norepinephrine levels in the 
melatonin group compared to the placebo group one hour after intake of the medication. This 
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could be because we obtained blood for catecholamine measurements while subjects were 
sitting, whereas previous studies found an effect of melatonin on plasma norepinephrine 
levels only when subjects were supine [44-46]. Although norepinephrine indeed turned out to 
be a significant predictor of fibrinogen and also showed a positive association with FVIII:C 
plasma levels, this catecholamine did not mediate the association between higher melatonin 
concentration and lower activity of these coagulation factors (Sobel test, data not shown). 
The mechanisms underlying this association therefore still need to be elucidated. 
Theoretically, it could be that by virtue of its anti-inflammatory and antioxydative properties 
[6] both of which are associated with coagulation activity [47, 48], melatonin could exert an 
indirect effect on plasma coagulation factor activites.  
Several factors add to the clinical significance of our study: First, we performed a 
placebo-controlled design in which study participants were randomly assigned to the 
respective medication condition of which they were unaware. Second, we recruited a 
homogenous sample of healthy non-smoking young men having reasonable health habits and 
being unmedicated. Third, we administered melatonin at a time when endogenous melatonin 
secretion is known to be low such that we could rule out confunding by endogenous 
melatonin production. Fourth, negligible confounding of melatonin effects on coagulation 
measures was further achieved by considering a priori a set of well-known demographic, 
metabolic, and neuroendocrine correlates of hemostatic function and of potential melatonin 
effects. Especially controlling for norepinephrine levels under melatonin administration was 
important given that norepinephrine has been shown to be lowered by oral melatonin 
administration in humans [44-46] and given that norepinephrine levels emerged as an 
independent predictor of some coagulation measures [40, 41]. Our study has also its 
limitations. The data cannot be generalized to women, elderly subjects, and patients with 
cardiovascular disease. However, it seemed prudent to first investigate the effect of melatonin 
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on coagulation activation in a healthy young population before subjecting patients with 
cardiovascular diseases to a study medication (i.e. melatonin) that has not been approved yet 
by Switzerland’s regulatory agency for therapeutic products (Swissmedics). We did not 
determine coagulation measures immediately before melatonin administration to compare 
these levels with those obtained 60 min after intake of the medication. 
Taken together, we found lower levels of the coagulation measures FVIII:C and 
fibrinogen one hour after oral intake of a single dose of 3 mg of melatonin compared to 
placebo medication. Moreover, at this time, higher melatonin plasma concentration predicted 
lower plasma levels of these coagulation measures. Such an effect may suggest potential 
implications for the use of melatonin as a theapeutic agent in patients at-risk of 
atherothrombotic events such as patients with CAD or systemic hypertension. However, 
future studies are needed to test the clinical significance of melatonin administration for 
coagulation activity in older age when the prevalence of CAD considerably increases and in 
patient populations. Moreover, the effect of repeated administration of melatonin on 
coagulation should be subject to further research. 
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Table 1. Characteristics of the 46 men studied 
 
    
Variable  Melatonin (n=25) Placebo (n=21) P-value 
    
Melatonin [pg/ml] 365.6 ± 103.2 2.25 ± 0.5 <0.001 
Age [yrs] 24.6 ± 0.7 25.1 ± 0.8 0.679 
Body mass index [kg/m2] 23.0 ± 0.6 22.7 ± 0.4 0.688 
Mean arterial pressure [mmHg] 94.1 ± 1.6 94.7 ± 2.2 0.812 
Heart rate [bpm] 71.5 ± 2.3 65.6 ± 2.5 0.087 
Norepinephrine [pg/ml] 321.6 ± 23.9 359.3 ± 31.1 0.334 
 
Values are given as means ± SEM 
Group comparison was by Student’s t-test 
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Table 2. Multivariate analysis of variance and covariance for coagulation factor levels as per medication group (n=46) 
       
 Melatonin (n=25) Placebo (n=21) P-MANOVA Melatonin (n=25) Placebo (n=21) P-MANCOVA 
       
Factor VII:C [%] 84 (77-91) 88 (80-95) 0.435 83 (76-91) 88 (80-96) 0.389 
Factor VIII:C [%] 82 (72-94) 101 (87-117) 0.047 81 (71-92) 103 (90-119) 0.018 
Fibrinogen [g/l] 1.98 (1.82-2.14) 2.20 (2.02-2.37) 0.071 1.92 (1.76-2.08) 2.26 (2.09-2.43) 0.007 
D-dimer [ng/ml] 125 (102-154) 119 (95-148) 0.717 123 (99-154) 121 (95-153) 0.883 
 
Values are given as means (FVII:C, fibrinogen) and as geometric means (FVIII:C, D-dimer) with 95% confidence interval  
Multivariate analysis of covariance (MANCOVA) controlled for age, body mass index, mean arterial pressure, heart rate, and norpeinephrine levels 
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Table 3. Multiple linear regression analysis of coagulation measures 
     
Variables entered Partial 
correlations 
Standardized 
β-coefficient 
P-value R2 change 
     
Dependent variable: Factor VIII clotting activity 
Age -.024 -.021 .882 <0.001 
Body mass index .060 .053 .711 0.003 
Mean arterial pressure .261 .245 .100 0.053 
Heart rate .014 .013 .929 <0.001 
Plasma norepinephrine -.339 -.330 .030 0.094 
Plasma melatonin -.326 -.310 .037 0.086 
 
Dependent variable Fibrinogen level 
Age .186 .168 .245 0.027 
Body mass index .120 .112 .453 0.011 
Mean arterial pressure -.160 -.152 .318 0.020 
Heart rate .365 .377 .019 0.118 
Plasma norepinephrine -.243 -.236 .126 0.048 
Plasma melatonin -.357 -.355 .022 0.112 
 
The R2 change value refers to the variance in FVIII:C and fibrinogen levels explained by an 
individual variable after controlling for the influence of all other variables of the model. 
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LEGEND TO FIGURE 1 
The partial residual plots depict the inverse and independent relationship between 
plasma melatonin levels and plasma levels of (A) clotting factor VIII activity (p=0.037) and 
(B) fibrinogen (p=0.029). Adjustment was made for age, body mass index, mean arterial 
pressure, heart rate, and plasma norepinephrine levels. All variables in the partial regression 
plots are residuals. 
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Figure 1. Independent relationship between melatonin and coagulation factor levels 
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